On July 3, 2025, HC Wainwright & Co. reiterated their "Buy" rating for Gain Therapeutics (GANX, Financial), maintaining their price target at $8.00 USD. This decision reflects the continued confidence in the company's growth prospects, as highlighted by analyst Raghuram Selvaraju.
The reiterated "Buy" rating and price target suggest a positive outlook for Gain Therapeutics (GANX, Financial), with no changes reported in the stock's expected value from prior assessments. The analyst's consistent valuation indicates a stable expectation for the stock’s performance in the market.
Investors following Gain Therapeutics (GANX, Financial) may consider this maintained price target and rating when evaluating their stock portfolio strategies. The report underscores a steady perception of the company's market position, aligning with prior expectations set by HC Wainwright & Co.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Gain Therapeutics Inc (GANX, Financial) is $8.00 with a high estimate of $12.00 and a low estimate of $5.00. The average target implies an upside of 390.80% from the current price of $1.63. More detailed estimate data can be found on the Gain Therapeutics Inc (GANX) Forecast page.
Based on the consensus recommendation from 7 brokerage firms, Gain Therapeutics Inc's (GANX, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Gain Therapeutics Inc (GANX, Financial) in one year is $2.00, suggesting a upside of 22.7% from the current price of $1.63. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Gain Therapeutics Inc (GANX) Summary page.
